You are here

  • Home
  • Archive
  • Volume 9, Issue 12
  • Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival

 

Online download statistics by month:

Online download statistics by month: December 2021 to March 2024

AbstractFullPdf
Dec 2021523529208
Jan 202228028599
Feb 202212012165
Mar 202212012873
Apr 2022828751
May 2022848557
Jun 20229710145
Jul 2022899132
Aug 202213313354
Sep 202210810866
Oct 202212312356
Nov 2022737571
Dec 2022717050
Jan 2023444430
Feb 2023444428
Mar 2023606440
Apr 2023555745
May 2023575738
Jun 2023505026
Jul 2023606038
Aug 2023404015
Sep 2023555536
Oct 2023484831
Nov 2023515119
Dec 2023404026
Jan 2024545530
Feb 2024494941
Mar 2024585864
Total266827081434